Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
1 other identifier
interventional
3,000
1 country
1
Brief Summary
This randomized quality improvement study evaluates the routine assessment of patient-reported heath status, using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) among adult outpatients seen in heart failure clinic or seen in general cardiology clinic with a history of heart failure. Patients will be randomized 4:1 to KCCQ-12 assessment or usual care. Participants randomized to KCCQ-12 assessment will complete the KCCQ-12 at every heart failure clinic visit. Their results will be available to clinicians to assist with clinical management. Heath status surveys will not be integrated into clinical care for patients in the usual care arm. The primary objective is to evaluate the impact of routine assessment of patient-reported heath status on clinical processes of care. As the primary outcome, we will evaluate clinician inertia by measuring the clinician action rating (CAR) - an aggregate count of medication changes, referrals, and diagnostic tests. As secondary outcomes, we will measure individual components of the composite outcome, therapy rates, resource utilization, and patient experience.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable heart-failure
Started Sep 2022
Shorter than P25 for not_applicable heart-failure
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 1, 2022
CompletedStudy Start
First participant enrolled
September 7, 2022
CompletedFirst Posted
Study publicly available on registry
October 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 7, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 7, 2023
CompletedOctober 3, 2022
September 1, 2022
1 year
September 1, 2022
September 29, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Clinician action rating
Aggregate count of medication changes, referrals, and diagnostic tests ordered per clinic visit
From date of randomization to study completion (up to 12 months)
Secondary Outcomes (18)
Medication Changes
From date of randomization to study completion (up to 12 months)
Referrals
From date of randomization to study completion (up to 12 months)
Diagnostic Tests
From date of randomization to study completion (up to 12 months)
Percentage of Patients on Beta-blocker Therapy and Median Dose Among Patients with Reduced Ejection Fraction
From date of randomization to study completion (up to 12 months)
Percentage of Patients on Renin-Angiotensin-Aldosterone System Inhibitors and Median Dose Among Patients with Reduced Ejection Fraction
From date of randomization to study completion (up to 12 months)
- +13 more secondary outcomes
Study Arms (2)
Health Status Assessment
EXPERIMENTALCompletion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
Usual Care
NO INTERVENTIONPatients will not complete a patient-reported health status measures.
Interventions
Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
Eligibility Criteria
You may qualify if:
- Seen in Stanford general cardiology clinic with a diagnosis of heart failure or cardiomyopathy or in heart failure clinic
You may not qualify if:
- Enrolled in PRO-HF trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford Hospital & Clinics
Stanford, California, 94305, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Instructor of Medicine
Study Record Dates
First Submitted
September 1, 2022
First Posted
October 3, 2022
Study Start
September 7, 2022
Primary Completion
September 7, 2023
Study Completion
December 7, 2023
Last Updated
October 3, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share